Form 4 for TVTX Travere Therapeutics, Inc.

Accepted 2026-04-15 21:46:38 ET · period of report 2026-04-13 · accession 0001902368-26-000005 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
T	2026-04-15 21:46	2026-04-13	TVTX	Inrig Jula	Chief MEDICAL Off	A - Grant	$0.00	+14.0K	119.7K	+13%	$0
MT	2026-04-15 21:46	2026-04-14+	TVTX	Inrig Jula	Chief MEDICAL Off	S - Sale	$42.01	-8,233	111.5K	-7%	-$345.9K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-04-13	A	A	14,000	$0.00	119,706	D	—	—	(F1) On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.
2	Common	Common Stock	2026-04-14	S	D	7,215	$41.93	112,491	D	—	—	(F2) Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
3	Common	Common Stock	2026-04-15	S	D	1,018	$42.61	111,473	D	—	—	(F3) This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.